Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder characterized by chronic inflammation and demyelination of peripheral nerves. Our company, a leading CRO in drug and therapy development services, is dedicated to advancing the understanding and therapeutic options for CIDP.
Overview of Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic neurological disorder classified as an autoimmune disease. It is characterized by the progressive destruction of the myelin sheath, the protective covering of nerve fibers, resulting in impaired nerve signal transmission. This demyelination leads to a wide range of symptoms, including muscle weakness, sensory loss, balance problems, and fatigue. The inflammatory process in CIDP is thought to be mediated by immune cells, specifically T-cells and B-cells, which infiltrate the peripheral nerves and promote an immune response against the myelin sheath.
Fig.1 Variants of CIDP. (Lehmann H. C., et al., 2019)
Therapy Discovery and Development for CIDP
Targeted therapies, such as rituximab, are being investigated for their potential in treating CIDP. Rituximab targets specific B-cell antigens involved in the immune response, while alemtuzumab depletes certain types of T cells. These therapies show promise in reducing inflammation and improving CIDP symptoms, particularly in cases with associated hematologic disorders. At our company, we specialize in offering tailor-made services for the development of diagnostics and therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). If you are interested in learning more about our therapy development services for CIDP, we invite you to click on the link below for further information.
Our Services
As a top CRO, we have a dedicated team of experts who specialize in creating animal models and in vitro models of CIDP. These models enable us to study the pathogenesis of the disease, evaluate the efficacy of potential therapies, and identify novel therapeutic targets. Through advanced techniques and state-of-the-art facilities, we investigate the pharmacokinetics, pharmacodynamics, and toxicology profiles of candidate drugs, ensuring their suitability for further development.
Active Immunization EAN Models
The experimental autoimmune neuritis (EAN) model, widely used for studying autoimmune demyelination processes related to CIDP, involves the active immunization of Lewis rats using a peptide derived from the major peripheral nervous system myelin protein.
Spontaneous Animal Models
We recognize the significance of spontaneous animal models in unraveling the complexity of CIDP and have dedicated ourselves to their development. Spontaneous animal models, such as those based on non-obese diabetic mice, have provided valuable insights into the chronicity of immunopathogenesis underlying CIDP.
One of the cell-based models we employ is the co-culture system, where primary human Schwann cells or Schwann cell lines are co-cultured with immune cells, such as T cells or macrophages, to recreate the inflammatory environment observed in CIDP.
Our organoid models exhibit key features of chronic inflammatory demyelinating polyneuropathy (CIDP), including immune cell infiltration, demyelination, and axonal damage, thus providing an invaluable tool for studying disease mechanisms and testing potential therapeutic strategies.
Our comprehensive services cover every stage of the drug development process, from drug discovery to preclinical studies. Beyond the aforementioned repertoire of services and models, our expertise extends to crafting personalized solutions and designing disease models that impeccably align with your unique needs. If our comprehensive range of offerings has piqued your interest, we wholeheartedly encourage you to connect with us without any hesitation.
Reference
- Lehmann Helmar Christoph, David Burke, and Satoshi Kuwabara. "Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment." Journal of Neurology, Neurosurgery & Psychiatry 90.9 (2019): 981-987.